You need to create a user account to read this article.
With a subscription you unlock more content on BioStock.
Evaxion Biotech has presented promising two-year data from its Phase II study of the personalized cancer vaccine EVX-01 at ESMO 2025. The vaccine, which is being tested in combination with MSD's Keytruda, achieved a response rate of...